In patients with NOD2-driven CD, gp130 blockade rescued the activated inflammatory program in the NOD2-deficient cells and complemented anti-tumor necrosis factor (TNF) therapy (Nayar et al., 2021). This evidence concerns the gene NOD2 and Cowden disease.